2 active not recruiting, 2 terminated, 1 completed, 1 recruiting. 3 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Recurrent Cutaneous Melanoma: new trials by email Literature Review of Recurrent Cutaneous Melanoma trials Research Report on Recurrent Cutaneous Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 28 | 2022-06-09 | 2026-07-22 |
| A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 60 | 2021-10-15 | 2026-09-29 |
| Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement Binimetinib, Conventional Surgery, Encorafenib - Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 3 | 2021-09-22 | 2026-10-06 |
| Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Cyclophosphamide, Etoposide - Recurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 12 | 2018-08-31 | 2026-03-20 |
| Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study - Metastatic Melanoma, Recurrent Cutaneous Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2016-12-16 | 2026-08-11 |
| Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Biospecimen Collection, Computed Tomography, Ipilimumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1301 | 2015-11-10 | 2026-10-01 |
Melanoma (6) · Bone Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Endocrine Gland Neoplasms (1) · Lung Neoplasms (1) · Lymphatic Metastasis (1) · Mesothelioma, Malignant (1) · Mouth Neoplasms (1) · Neoplasm Metastasis (1) · Pharyngeal Neoplasms (1) · Sarcoma (1) · Skin Neoplasms (1) · Thyroid Neoplasms (1) · Urologic Neoplasms (1)
Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Nerve Tissue (6) · Neuroectodermal Tumors (6) · Neuroendocrine Tumors (6) · Nevi and Melanomas (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Skin Neoplasms (5) · Lung Diseases (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Magnetic Resonance Spectroscopy (3) · Biopsy (2) · Specimen Handling (2) · pembrolizumab (2) · CTLA-4 Antigen (1) · Cyclophosphamide (1) · Etoposide (1) · Interferon alpha-2 (1) · Introns (1) · Ipilimumab (1) · Nivolumab (1) · Pharmacogenomic Testing (1) · Surgical Procedures, Operative (1) · alovudine (1) · binimetinib (1)
National Cancer Institute (NCI) (3) · ECOG-ACRIN Cancer Research Group (1) · Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1)
United States (6) · Canada (1) · Ireland (1)
Ahmad Tarhini (1) · Demetrios Petropoulos (1) · Joshua Veatch (1) · Leslie A Fecher (1) · Sapna Patel (1) · Stergios J Moschos (1)
U10CA180820 (2), P30CA016672 (1), U10CA180888 (1), UM1CA186644 (1), UM1CA186686 (1), UM1CA186688 (1), UM1CA186689 (1), UM1CA186690 (1), UM1CA186691 (1), UM1CA186704 (1), UM1CA186709 (1), UM1CA186712 (1), UM1CA186716 (1), UM1CA186717 (1)